GR1802
As of the edition of 20 October 2026, GR1802 is a drug known only by a code name: in active development; acts on IL4R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 8, 0 stopped early
- Disease areas
- Immune system; Lungs and airways; Ear, nose and throat; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL4R | Interleukin-4 receptor subunit alpha | P24394 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 0 | 1 | 0 |
| Phase 3 | 4 | 0 | 3 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Genrix Biopharmaceutical | Lead sponsor of trials | 2022 to now |